TrialAnnals of hematology2015

Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013).

Theo de Witte et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.